Financials in USD. Standardized financial statements.
A compact view of how Opiant Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $40.73M | $27.40M | $38.24M | $13.51M | $18.45M | $9.90M | $1.55M | $0 | $0 | $0 |
| Revenue Growth? | +48.6% | -28.3% | +183.0% | -26.7% | +86.4% | +538.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $9.07M | $6.20M | $7.72M | $1.49M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $31.66M | $21.20M | $30.52M | $12.02M | $18.45M | $9.90M | $1.55M | $0 | $0 | $0 |
| Gross Margin? | +77.7% | +77.4% | +79.8% | +89.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $26.50M | $23.45M | $19.61M | $33.21M | $11.35M | $17.64M | $8.45M | $11.30M | $4.29M | $12.34M |
| Operating Income? | $5.16M | -$2.24M | $10.91M | -$21.19M | $7.09M | -$7.74M | -$6.90M | -$11.30M | -$4.29M | -$12.34M |
| EBITDA? | $5.83M | -$1.55M | $11.15M | -$21.14M | $7.14M | -$7.80M | -$7.01M | -$11.32M | -$4.10M | -$12.36M |
| Income Before Tax | $3.03M | -$2.29M | $11.42M | -$21.14M | $7.13M | -$7.81M | -$7.04M | -$11.48M | -$4.66M | -$12.42M |
| Income Tax Expense | $24,270 | -$426,000 | -$177,000 | $51,283 | $550,474 | -$51,997 | $0 | $0 | $0 | $37,296 |
| Net Income? | $3.01M | -$1.86M | $11.59M | -$21.20M | $6.58M | -$7.81M | -$7.04M | -$11.48M | -$4.66M | -$12.42M |
| EPS? | $0.68 | $-0.44 | $2.88 | $-7.10 | $3.27 | $-4.09 | $-3.88 | $-6.57 | $-3.25 | $-11.96 |
| Diluted EPS? | $0.51 | $-0.44 | $2.17 | $-7.10 | $2.94 | $-4.09 | $-3.88 | $-6.57 | $-3.25 | $-11.96 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality